These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29526777)

  • 41. Oxyphil cell function in secondary parathyroid hyperplasia.
    Tanaka Y; Funahashi H; Imai T; Seo H; Tominaga Y; Takagi H
    Nephron; 1996; 73(4):580-6. PubMed ID: 8856255
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of Anabolic Effect of Calcitriol with Osteoclast-Derived Wnt 10b Secretion.
    Lu CL; Shyu JF; Wu CC; Hung CF; Liao MT; Liu WC; Zheng CM; Hou YC; Lin YF; Lu KC
    Nutrients; 2018 Aug; 10(9):. PubMed ID: 30149605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiac effect of vitamin D receptor modulators in uremic rats.
    Mizobuchi M; Ogata H; Yamazaki-Nakazawa A; Hosaka N; Kondo F; Koiwa F; Kinugasa E; Shibata T
    J Steroid Biochem Mol Biol; 2016 Oct; 163():20-7. PubMed ID: 27072785
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oxyphil cell metaplasia in the parathyroids is characterized by somatic mitochondrial DNA mutations in NADH dehydrogenase genes and cytochrome c oxidase activity-impairing genes.
    Müller-Höcker J; Schäfer S; Krebs S; Blum H; Zsurka G; Kunz WS; Prokisch H; Seibel P; Jung A
    Am J Pathol; 2014 Nov; 184(11):2922-35. PubMed ID: 25418474
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Microwave ablation: an effective treatment for mild-to-moderate secondary hyperparathyroidism in patients undergoing haemodialysis.
    Wang G; Liu S; Liu X; Qian L; Diao Z; Liu W
    Int J Hyperthermia; 2017 Dec; 33(8):946-952. PubMed ID: 28768451
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia.
    Shiizaki K; Hatamura I; Negi S; Narukawa N; Mizobuchi M; Sakaguchi T; Ooshima A; Akizawa T
    Kidney Int; 2003 Sep; 64(3):992-1003. PubMed ID: 12911549
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of uremic ultrafiltrate on the regulation of the parathyroid cell cycle by calcitriol.
    Canalejo A; Almadén Y; De Smet R; Glorieux G; Garfia B; Luque F; Vanholder R; Rodríguez M
    Kidney Int; 2003 Feb; 63(2):732-7. PubMed ID: 12631141
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of parathyroid mass on the regulation of PTH secretion.
    Lewin E; Olgaard K
    Kidney Int Suppl; 2006 Jul; (102):S16-21. PubMed ID: 16810305
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravenous calcitriol normalizes insulin sensitivity in uremic patients.
    Kautzky-Willer A; Pacini G; Barnas U; Ludvik B; Streli C; Graf H; Prager R
    Kidney Int; 1995 Jan; 47(1):200-6. PubMed ID: 7731147
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [MIBI and parathyroid gland function in secondary hyperparathyroidism].
    Martín F; Sarró F; Verdú J; González A; Martínez F
    Nefrologia; 2004; 24(4):344-50. PubMed ID: 15455494
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
    Brancaccio D; Bommer J; Coyne D
    Drugs; 2007; 67(14):1981-98. PubMed ID: 17883283
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Binding of highly concentrated maxacalcitol to the nuclear vitamin D receptors of parathyroid cells.
    Shiizaki K; Hayakawa N; Imazeki I; Hatamura I; Okada T; Negi S; Sakaguchi T; Shigematsu T; Akizawa T
    Nephrol Dial Transplant; 2007 Apr; 22(4):1078-86. PubMed ID: 17234669
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emerging drugs for secondary hyperparathyroidism.
    Cozzolino M; Tomlinson J; Walsh L; Bellasi A
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):197-208. PubMed ID: 25702624
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Significance of Ultrasound in Determining Whether SHPT Patients Are Sensitive to Calcitriol Treatment.
    Liang XX; Li F; Gao F; Li CX; Qiao XH; Zhang JJ; Du LF
    Biomed Res Int; 2016; 2016():6193751. PubMed ID: 27034943
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism.
    Rodriguez M; Nemeth E; Martin D
    Am J Physiol Renal Physiol; 2005 Feb; 288(2):F253-64. PubMed ID: 15507543
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Surgical management of secondary hyperparathyroidism in uremia.
    Tominaga Y
    Am J Med Sci; 1999 Jun; 317(6):390-7. PubMed ID: 10372839
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pathogenesis of refractory secondary hyperparathyroidism.
    Rodriguez M; Canalejo A; Garfia B; Aguilera E; Almaden Y
    Kidney Int Suppl; 2002 May; (80):155-60. PubMed ID: 11982830
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Direct injection of calcitriol or its analog improves abnormal gene expression in the hyperplastic parathyroid gland in uremia.
    Shiizaki K; Fukagawa M; Yuan Q; Hatamura I; Nii-Kono T; Saji F; Shigematsu T; Akizawa T
    Am J Nephrol; 2008; 28(1):59-66. PubMed ID: 17901691
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.
    Reichel H
    Nephron Clin Pract; 2010; 114(4):c268-76. PubMed ID: 20090369
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease.
    Cozzolino M; Ciceri P; Volpi EM; Olivi L; Messa PG
    Blood Purif; 2009; 27(4):338-44. PubMed ID: 19295196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.